These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 1324257

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. High-level resistance to zidovudine but not to zalcitabine or didanosine in human immunodeficiency virus from children receiving antiretroviral therapy.
    Husson RN, Shirasaka T, Butler KM, Pizzo PA, Mitsuya H.
    J Pediatr; 1993 Jul; 123(1):9-16. PubMed ID: 8391570
    [Abstract] [Full Text] [Related]

  • 4. Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: adverse effects.
    Saag MS.
    Hosp Pract (Off Ed); 1992 Aug; 27 Suppl 2():26-36. PubMed ID: 1324255
    [Abstract] [Full Text] [Related]

  • 5. ACTG 175 and Delta.
    Torres G.
    GMHC Treat Issues; 1995 Oct; 9(10):2-3. PubMed ID: 11362915
    [Abstract] [Full Text] [Related]

  • 6. Treatment of HIV infection: the antiretroviral nucleoside analogues. Introduction.
    McLeod GX, Hammer SM.
    Hosp Pract (Off Ed); 1992 Aug; 27 Suppl 2():3-4. PubMed ID: 1324256
    [No Abstract] [Full Text] [Related]

  • 7. Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. HIV Trialists' Collaborative Group.
    Lancet; 1999 Jun 12; 353(9169):2014-25. PubMed ID: 10376616
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. ACTG 175: new insights into treating patients with intermediate-stage HIV disease.
    Folkers G.
    NIAID AIDS Agenda; 1995 Dec 12; ():4-5. PubMed ID: 11363352
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Studies of zidovudine in combination with didanosine and zalcitabine.
    Jablonowski H.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec 12; 10 Suppl 1():S52-6. PubMed ID: 8595509
    [Abstract] [Full Text] [Related]

  • 12. 3TC approval may revive AZT's appeal.
    Vazquez E.
    Posit Aware; 1996 Dec 12; 7(1):8-9. PubMed ID: 11363136
    [Abstract] [Full Text] [Related]

  • 13. Benefits of combination therapy confirmed.
    Cheng B.
    PI Perspect; 1995 Dec 12; (no 17):3-4. PubMed ID: 11363111
    [Abstract] [Full Text] [Related]

  • 14. Study results at a glance.
    AIDS Alert; 1995 Nov 12; 10(11):134. PubMed ID: 11362922
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. 3TC/AZT: just another combination.
    GMHC Treat Issues; 1995 Dec 12; 9(12):2. PubMed ID: 11362997
    [Abstract] [Full Text] [Related]

  • 17. Outdated yet out-of-reach: AIDS society treatment guidelines at the International Conference.
    Torres G.
    GMHC Treat Issues; 1996 Sep 12; 10(9):7, 10-1. PubMed ID: 11363842
    [Abstract] [Full Text] [Related]

  • 18. Studies confirm value of early and combination treatments.
    Vazquez E.
    Posit Aware; 1995 Sep 12; VI(6):8. PubMed ID: 11363148
    [Abstract] [Full Text] [Related]

  • 19. 3TC approved: now for the tough questions.
    Mascolini M.
    J Int Assoc Physicians AIDS Care; 1995 Dec 12; 1(11):6-8. PubMed ID: 11363101
    [Abstract] [Full Text] [Related]

  • 20. A comparison of zidovudine, didanosine, zalcitabine and no antiretroviral therapy in patients with advanced HIV disease.
    Torres RA, Barr MR, McIntyre KI, Thornton JR, Shay WM, Feldman RD, George NJ, Britton DJ.
    Int J STD AIDS; 1995 Dec 12; 6(1):19-26. PubMed ID: 7727578
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.